173 results on '"Krebs, Matthew G"'
Search Results
2. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
3. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
4. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
5. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
6. The evolution of lung cancer and impact of subclonal selection in TRACERx
7. Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
8. Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases
9. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
10. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
11. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
12. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
13. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer
14. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
15. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
16. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
17. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
18. RETaliation—Tackling Rare Resistance Alterations to Osimertinib
19. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer
20. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
21. Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
22. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer
23. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer
24. Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA):An open-label, multicenter, phase 1/2, basket study
25. Body composition and lung cancer-associated cachexia in TRACERx
26. The evolution of non-small cell lung cancer metastases in TRACERx
27. The evolution of lung cancer and impact of subclonal selection in TRACERx
28. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
29. Digital ECMT Cancer Trial Matching Tool: an Open Source Research Application to Support Oncologists in the Identification of Precision Medicine Clinical Trials
30. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
31. Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin
32. Abstract CT201: Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
33. Abstract 2808: cfDNA multi-omics profiling and tissue of origin predictions in cancers of unknown primary
34. Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response
35. Abstract CT198: Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study
36. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
37. Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
38. Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
39. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
40. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC
41. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
42. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
43. Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer
44. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
45. Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
46. Enrolment of older adults with cancer in early phase clinical trials—an observational study on the experience in the north west of England
47. Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials
48. Molecular analysis of circulating tumour cells —biology and biomarkers
49. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
50. EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.